Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 9/20 | 0.60 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | BAG3 | O95817 | 1/20 | 0.46 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172642 | 1.00 | HSD17B3 (0.60) | HSD17B3CISD1HPGDMEN1KMT2A | |
| SCHEMBL12712434 | 0.87 | BAG3 (0.51) | HSD17B3HPGDMEN1KMT2ABAG3 | |
| SCHEMBL12712440 | 0.87 | BAG3 (0.51) | HSD17B3HPGDMEN1KMT2ABAG3 | |
| SCHEMBL12406432 | 0.85 | MAPT (0.58) | HSD17B3CISD1HPGDMEN1KMT2A | |
| SCHEMBL2175717 | 0.85 | MAPT (0.58) | HSD17B3CISD1HPGDMEN1KMT2A | |
| SCHEMBL1614684 | 0.84 | SLC2A1 (0.63) | HSD17B3HPGDMEN1KMT2ABAG3 | |
| SCHEMBL2171564 | 0.84 | SLC2A1 (0.63) | HSD17B3HPGDMEN1KMT2ABAG3 | |
| SCHEMBL2171569 | 0.84 | SLC2A1 (0.63) | HSD17B3HPGDMEN1KMT2ABAG3 | |
| SCHEMBL1614725 | 0.84 | SLC2A1 (0.63) | HSD17B3HPGDMEN1KMT2ABAG3 | |
| SCHEMBL1614983 | 0.82 | HPGD (0.46) | HSD17B3CISD1HPGDKMT2ACGAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | claimed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | claimed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | claimed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | claimed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | claimed |
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | AR, ESRRB, KLK3 | HSD17B3 48/4885CISD1 1747/4885HPGD 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.